Scarica l'app Stockscreener
5.12
0.99%
0.05
Dopo l'orario di chiusura:
5.01
-0.11
-2.15%
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating - marketscreener.com
Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12. - moomoo.com
Atea Pharmaceuticals, Inc. (AVIR) stock price, news, quote and history - Yahoo Finance UK
Atea Pharmaceuticals Q2 2026 Earnings Call Transcript - marketbeat.com
Atea Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-08-12 - Seeking Alpha
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Atea Pharmaceuticals Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing - Kalkine Media
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS - marketbeat.com
Earnings call transcript: Atea beats Q2 2026 EPS view but shares fall after hours - Investing.com
ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings - Quiver Quantitative
Atea Pharmaceuticals (NASDAQ: AVIR) advances HCV Phase 3 as losses widen - Stock Titan
Atea Hepatitis C Regimen Posts 93.9% Sustained Response - Stock Titan
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - Sahm
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks - webull.com
Arrowstreet Capital Limited Partnership Takes Position in Atea Pharmaceuticals, Inc. $AVIR - marketbeat.com
Atea's Aug. 12 webcast will include a business update - Stock Titan
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - Yahoo Finance
Atea Pharmaceuticals (AVIR) Projected to Post Earnings on Thursday - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Atea posts late-stage trial win for hepatitis C drug (AVIR) - Seeking Alpha
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial - Benzinga
Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus - marketscreener.com
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus - GlobeNewswire
AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus - European AIDS Treatment Group
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Cash Flow - TradingKey
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BML Capital Management LLC Sells 431,343 Shares of Atea Pharmaceuticals, Inc. $AVIR - MarketBeat
Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy - TipRanks
Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support LevelIchimoku Kumo Twist - dars.gov.et
Atea Pharmaceuticals Starts Phase 1 AT-587 Trial - t.co
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
Atea Pharmaceuticals initiates Phase 1 trial for AT-587 - scanx.trade
AVIR Q1 2026 Earnings: Narrower-than-expected Loss Drives Modest Stock GainCost Structure Review - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) Proxy filing Summary - Quartr
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
Atea Pharmaceuticals (AVIR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary - Quartr
Atea Pharmaceuticals Inc (AVIR:UW): Stock Price, Quote and News - BNN Bloomberg
AVIRAtea Pharmaceuticals Inc Short Interest - Finviz
Atea Pharmaceuticals Gains 2.67% as Stock Approaches Key Resistance LevelMoney Flow Index - dars.gov.et
Atea Pharmaceuticals (AVIR) Q1 2026 Earnings: Beat on EPS Despite Pre-Revenue Status; Stock Climbs 2.67%Consensus Forecast Report - dars.gov.et
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Enterprise value to EBIT forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):